Safety of Opioids since the introduction of OxyNEO (Q13-03B)

Safety of Opioids since the introduction of OxyNEO (Q13-03B)

Safety of Opioids since the introduction of OxyNEO (Q13-03B)

Q13-03B

Manuscripts

Gomes T, Paterson JM, Mukati M, Henry D; Canadian Network for Observational Drug Effect Studies investigators. Retrospective analysis of trends in dispensing long-acting non–tamper-resistant oxycodone near the Canada–United States border. CMAJ Open. 2015 Apr 2;3(2):E231-5.

Gomes T, Mastorakos A, Paterson JM, Sketris I, Caetano P, Greaves S, Henry D,for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Changes in the dispensing of opioid medications in Canada following the introduction of a tamper-deterrent formulation of long-acting oxycodone: a time series analysis. CMAJ Open. 2017 November 5(4); E800-E807.

Gomes T, Jain S, Paterson JM, Sketris I, Caetano P, Henry D, for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Trends and uptake of new formulations of controlled-release oxycodone in Canada. Pharmacoepidemiol Drug Saf.2018 May;27(5):520-525.

Presentations

Project Team

Project Co-Lead
Dan Chateau PhD
Manitoba
Project Co-Lead
Tara Gomes MHSc
Ontario
Steering Committee Liaison
Michael Paterson MSc
Ontario
Steering Committee Liaison
David Henry MBChB, MRCP, FRCP (Edin)
Ontario
Lead Analyst
Matthew Dahl BSc
Manitoba
Site Investigator
David Blackburn
Saskatchewan
Site Investigator
Madeleine Durand MD, MSc, FRCPC
Quebec
Site Investigator
Tara Gomes MHSc
Ontario
Site Investigator
Patricia Caetano PhD
Manitoba
Site Investigator
Colin R. Dormuth ScD
British Columbia
Site Investigator
Lauren Bresee PhD
Alberta
Co-Site Investigator
Hala Tamim PhD
Atlantic
Co-Site Investigator
Ingrid Sketris Pharm D, MPA(HSA)
Atlantic
Analyst
Xinya Lu PhD
Saskatchewan
Analyst
Vicki Ling
Ontario
Analyst
Steve Doucette MSc
Atlantic
Analyst
Matthew Dahl BSc
Manitoba
Analyst
Anat Fisher MD, PhD
British Columbia
Analyst
Jianguo (James) Zhang MSc
Alberta